Deferoxamine versus combined therapy for chelating liver, spleen and bone marrow iron in β-thalassemic patients: A quantitative magnetic resonance imaging study

Hemoglobin

Volumn 34, Issue 1, 2010, Pages 95-106

  Drakonaki, Eleni E ^a   Maris, Thomas G ^a   Maragaki, Stella ^b   Klironomos, Vaggelis ^b   Papadakis, Alex ^b   Karantanas, Apostolos H ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b Venizelion General Hospital   (Greece)

Author keywords

Bone marrow; Chelation; Iron; Liver; Magnetic resonance imaging (MRI); Spleen; Thalassemia

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN;

ADULT; ARTICLE; BETA THALASSEMIA; CHELATION THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; IRON CHELATION; IRON OVERLOAD; MALE; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING;

BETA-THALASSEMIA; BONE MARROW; CHELATION THERAPY; DEFEROXAMINE; DRUG THERAPY, COMBINATION; FEMALE; FERRITINS; HUMANS; IRON; LIVER; MAGNETIC RESONANCE IMAGING; MALE; PROSPECTIVE STUDIES; PYRIDONES; SPLEEN;

EID: 76449107180     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630260903546445     Document Type: Article

References (37)

1. Weatherall DJ, Clegg JB, Na-Nakorn S, Wasi P. The pattern of disordered haemoglobin synthesis in homozygous and heterozygous b-thalassaemia. Br J Haematol. 1969;16(3):251-267.
2. Siegelman ES, Mitchell DG, Rubin R, et al. Parenchymal versus reticuloendothelial iron overload in the liver: distinction with MR imaging. Radiology. 1991;179(3):361-366.
3. Yoon DY, Choi BI, Han JK, Han MC, Park MO, Suh SJ. MR findings of secondary hemochromatosis: transfusional vs erythropoietic. J Comput Assist Tomogr. 1994;1(3):416-419.
4. Gandon Y, Guyader D, Heautot JF, et al. Hemochromatosis: diagnosis and quantification of liver iron with gradient echo MR imaging. Radiology. 1994;193(2):533-538.
5. Gandon Y, Olivie D, Guyader D, et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet. 2004; 363(9406):357-362.
6. Papakonstantinou OG, Maris TG, Kostaridou V, et al. Assessment of liver iron overload by T2-quantitative magnetic resonance imaging: correlation of T2-QMRI measurements with serum ferritin concentration and histologic grading of siderosis. Magn Reson Imaging. 1995;13(7):967-977.
7. Fenzi A, Bortolazzi M, Marzola P. Comparison between signal-to-noise ratio, liver-to-muscle ratio, and 1/T2 for the noninvasive assessment of liver iron content by MRI. J Magn Reson Imaging. 2003;17(5):589-592.
8. Argyropoulou MI, Metafratzi Z, Kiortsis DN, Bitsis S, Tsatsoulis A, Efremidis S. T2 relaxation rate as an index of pituitary iron overload in patients with b-thalassemia major. Am J Roentgenol. 2000;175(6):1567-1569.
9. Midiri M, Lo Casto A, Sparacia G, et al. MR imaging of pancreatic changes in patients with transfusion- dependent b-thalassemia major. Am J Roentgenol. 1999;173(1):187-192.
10. Drakonaki E, Papakonstantinou O, Maris T, Vasiliadou A, Papadakis A, Gourtsoyiannis N. Adrenal glands in b-thalassemia major: magnetic resonance (MR) imaging features and correlation with iron stores. Eur Radiol. 2005;15(12):2462-2468.
11. Papakonstantinou O, Maris TG, Kostaridou S, Ladis V, Vasiliadou A, Gourtsoyiannis NC. Abdominal lymphadenopathy in b-thalassemia: MRI features and correlation with liver iron overload and posttransfusion chronic hepatitis C. Am J Roentgenol. 2005;185(1):219-224.
12. Kolnagou A, Economides Ch, Eracleous E, Kontoghiorghes GJ. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. Hemoglobin. 2008;32(1-2):41-47.
13. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in b-thalassaemia. Lancet. 2002;360(9332):516-520.
14. Glickstein H, El RB, Shvartsman M, Cabantchik ZI. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood. 2005;106(9):3242-3250.
15. Link G, Konijn AM, Breuer W, Cabantchik ZI, Hershko C. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med. 2001;138(2):130-138.
16. Ooi GC, Khong PL, Chan GC, et al. Magnetic resonance screening of iron status in transfusiondependent b-thalassaemia patients. Br J Haematol. 2004;124(3):385-390.
17. Jensen PD. Evaluation of iron overload. Br J Haematol. 2004;124(6):697-711.
18. Mourad FH, Hoffbrand AV, Sheikh-Taha M, et al. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol. 2003;121(1):187-189.
19. Daar S, Pathare AV. Combined therapy with desferrioxamine and deferiprone in b thalassemia major patients with transfusional iron overload. Ann Hematol. 2006;85(5):315-319.
20. Kattamis A, Ladis V, Berdousi H, et al. Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial. Blood Cells Mol Dis. 2006;36(1):21-25.
21. Galanello R, Kattamis A, Piga A, et al. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica. 2006;91(9):1241-1243.
22. Christoforidis A, Haritandi A, Tsatra I, Tsitourides I, Karyda S, Athanassiou-Metaxa M. Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with b-thalassaemia major: comparison between different chelation regimens. Eur J Haematol. 2007;78(1):52-57.
23. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115(14):1876-1884.
24. Perifanis V, Christoforidis A, Vlachaki E, Tsatra I, Spanos G, Athanassiou-Metaxa M. Comparison of effects of different long-term iron-chelation regimens on myocardial and hepatic iron concentrations assessed with T2* magnetic resonance imaging in patients with b-thalassemia major. Int J Hematol. 2007;86(5):385-389.
25. El-Beshlawy A, Manz C, Naja M, et al. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience. Ann Hematol. 2008;87(7):545-550.
26. Tsironi M, Assimakopoulos G, Polonofi K, Rigaki K, Aessopos A. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in b-thalassemia. Hemoglobin. 2008;32(1-2):29-34.
27. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology Am Soc Hematol Educ Program. 2001:47-61.
28. Breuer W, Empers MJJ, Pootrakul P, et al. Deferoxamine chelatable iron, a component of serum non-transfusion-bound iron, used for assessing chelation therapy. Blood. 2001;97(3):792-798.
29. Cohen AR, Galanello R, Pennell DJ, Cunningham MJ, Vichinsky E. Thalassemia. Hematology Am Soc Hematol Educ Program. 2004:14-34.
30. Agarwal MB, Gupte SS, Viswanathan C, et al. Long-term assessment of efficacy and safety of deferiprone, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br J Haematol. 1992; 82(2):460-466.
31. Galanello R. Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective. Ther Clin Risk Manag. 2007;3(5):795-805.
32. Kolnagou A, Economides Ch, Eracleous E, Kontoghiorghes GJ. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. Hemoglobin. 2008;32(1-2):41-47.
33. Drakonaki EE, Maris TG, Papadakis A, Karantanas AH. Bone marrow changes in b-thalassemia major: quantitative MR imaging findings and correlation with iron stores. Eur Radiol. 2007;17(7):2079-2087.
34. Papakonstantinou O, Drakonaki EE, Maris T, Vasiliadou A, Papadakis A, Gourtsoyiannis N. MR imaging of spleen in b-thalassemia major. Abdom Imaging. 2006:12.
35. Kaltwasser JP, Gottschalk R, Schalk KP, et al. Non-invasive quantitation of liver iron-overload by magnetic resonance imaging. Br J Haematol. 1990;74(3):360-363.
36. Mazza P, Giua R, De Marco S, et al. Iron overload in thalassemia: comparative analysis of magnetic resonance imaging, serum ferritin and iron content of the liver. Haematologica. 1995;80(5):398-404.
37. Papakonstantinou O, Alexopoulou E, Economopoulos N, et al. Assessment of iron distribution between liver, spleen, pancreas, bone marrow, and myocardium by means of R2 relaxometry with MRI in patients with b-thalassemia major. J Magn Reson Imaging. 2009;29(4):853-859.